The Swedish Patent Office PCT International Application

PCT/FI2004/000447 02.11.2005 10/59318

76

## Amended claims 21 October 2005

1. A sulphonamide derivative of formula (I) or a physiologically acceptable salt thereof,

5

15

20

25

$$\begin{array}{c|c} R_{C} & & & \\ \hline & & & \\ (CH_{2})_{m} & & \\ N-R_{B} & & \\ SO_{2} & & \\ R_{A} & & & \end{array}$$

where

R<sub>C</sub> is an optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or

R<sub>C</sub> forms together with the phenyl ring to which it is attached a ben-zodioxolyl group, or

R<sub>C</sub> is -NR<sup>1</sup>R<sup>2</sup>, where

R<sup>1</sup> is hydrogen or alkyl,

R<sup>2</sup> is alkyl or an optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or

R<sup>1</sup> and R<sup>2</sup> taken together with the nitrogen atom to which they are attached form a heterocyclic group, which may contain one or more additional heteroatoms selected from O and N and which may be substituted, or

R<sup>1</sup> and R<sup>2</sup> are absent and the nitrogen atom together with the adjacent carbon atom forms a heterocyclic ring, which may contain one or more additional heteroatoms selected from N, O and S and which may be substituted, provided that the nitrogen atom together with the benzene moiety does not form an isoquinoline or an indol-7-yl ring,

m is 0 or 1,

RA is a group having the formula

-(CH=CH)<sub>n</sub> -(CH=CH)<sub>n</sub> 
$$R^3$$
 (A),  $R^4$  (B) or

-(CH=CH)
$$_{n}$$
 (C)

wherein

n is 0,

10

15

25

R<sup>3</sup> and R<sup>4</sup> represent each independently hydrogen, halogen, aryl, alkoxy, carboxy, hydroxy, alkoxyalkyl, alkoxycarbonyl, cyano, trifluoromethyl, alkanoyl, alkanoylamino, trifluorometoxy, an optionally substituted aryl or heterocyclic group, and

R<sub>B</sub> is hydrogen or alkyl.

- 2. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent methyl, R<sup>3</sup> is 2-chloro and R<sup>4</sup> is 4-chloro.
- 3. A derivative according to claim 1 where  $R^1$  is hydrogen,  $R^2$  is 4,6-dimethylpyrimidin-2-yl,  $R^3$  is chloro and  $R^4$  is chloro.
- 4. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent 20 methyl, R<sup>3</sup> is hydrogen and R<sup>4</sup> is 3,4-dimethoxyphenyl.
  - 5. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent methyl, R<sup>3</sup> is hydrogen and R<sup>4</sup> is 4-fluorophenyl.
  - 6. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent methyl, R<sup>3</sup> is hydrogen and R<sup>4</sup> is bromo.
  - 7. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide.
  - 8. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-sulfonic acid (2-methyl-benzooxazol-6-yl)-amide.
- 9. A derivative according to claim 1, which is 2,4-dichloro-N-(1,2-30 dimethyl-1H-indol-5-yl)-N-methyl-benzenesulfonamide.
  - 10. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-sulfonic acid (4-dimethylaminophenyl)-methyl-amide.


- 11. A derivative according to claim 1, which is N-[4-(dimethylamino)phenyl]-4'-fluoro-2'-methyl-1,1'-biphenyl-3-sulfonamide.
- 12. A derivative according to any of claims 1 to 11 for use as an inhibitor for collagen receptor integrins.
- 13. A derivative according to any of the claims 1 to 11 for use as an inhibitor for  $\alpha 2\beta 1$  integrin.

5

10

15

- 14. A derivative according to any of claims 1 to 11 for use as an  $\alpha 2\beta 1$  integrin I domain inhibitor.
- 15. A derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof for use as a medicament.
- 16. A derivative according to claim 15 for use as a medicament for treating thrombosis and cancer spread.
- 17. The use of a derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof for preparing a pharmaceutical composition for treating disorders relating to thrombosis and cancer spread.
- 18. A pharmaceutical composition comprising an effective amount of a derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
- 19. A process for preparing a benzene sulphonamide according to claim 1, comprising reacting a compound of formula (II)



where  $R_{\text{B}}$ ,  $R_{\text{C}}$  and m are as defined above, with a compound of formula (III)

R<sub>A</sub>-SO₂hal (III)

where RA is as defined above and hal is halogen.